Playback speed
10 seconds
2020 SOHO Update on Immunotherapy in AML: Gemtuzumab Ozogamicin Plus 7+3 vs. 7+3, CD123-Targeting ADC IMGN632 & Azacitidine + Nivolumab in R/R AML, Anti-CD47 Antibody Magrolimab + Azacitidine
By
2nd SOHO Italian Conference
FEATURING
Naval Daver
By
2nd SOHO Italian Conference
FEATURING
Naval Daver
122 views
December 7, 2020
Comments 0
Login to view comments.
Click here to Login
Leukemia